CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial Intravascular ultrasound predictors for edge restenosis after newer generation drug-eluting stent implantation SPECT and PET in ischemic heart failure Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery Consensus from the 5th European Bifurcation Club meeting

Recommandation StatementDecember 10, 2018 [Epub ahead]

JOURNAL:Arterioscler Thromb Vasc Biol. Article Link

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

CB Newman and and on behalf of the American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Keywords: statin; ASCVD; risk; side effects; benefits

FULL TEXT PDF